Everlum Bio utilizes a personalized, multi-modality approach to drug development, employing techniques such as gene therapy, antisense oligonucleotides, and small molecule screening to create tailored therapeutics for rare diseases. The company addresses the lengthy and costly traditional drug development process by providing families with a transparent and expedited pathway to effective treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug development for rare diseases is often slow, expensive, and lacks transparency, leaving families feeling overwhelmed and without clear guidance. The lengthy process can result in significant financial burdens and emotional distress as patients wait for potential treatments.
Solution
Everlum Bio offers a personalized, multi-modality approach to expedite the development of tailored therapeutics for rare diseases. The company utilizes techniques such as gene therapy, antisense oligonucleotides (ASOs), and small molecule screening, guided by a proprietary AI platform and collaboration with leading scientists. Everlum Bio's approach includes a comprehensive "Cure Plan," cell line development using induced pluripotent stem cells (iPSCs) for drug candidate screening, and animal model testing to ensure therapeutic efficacy and safety. The company aims to provide families with a transparent and direct path to customized treatment options, including access to therapeutics through N=1 FDA trials.
Target Audience
The primary target audience includes families affected by rare diseases who are seeking faster, more personalized, and transparent treatment options, as well as foundations focused on specific rare diseases.
Features
- Proprietary AI platform for identifying optimal therapeutic strategies
- Multi-modality approach, including gene therapy, ASOs, and small molecule screening
- Cell line development using patient-derived iPSCs for drug screening and target identification
- Animal model testing to validate therapeutic efficacy and safety
- Assay development to determine the effectiveness of created therapeutics
- ASOs designed to modulate specific genes and screened in cell lines
- Repurposing of existing drugs to mitigate symptoms
- N=1 FDA trials for immediate access to customized treatment options